HIV patients with liver failure get new drug combo tested in transplant study
NCT ID NCT01022476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection medicines after transplant. The goal was to keep HIV under control while managing the transplant safely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Médecine Interne, Hôpital de Bicêtre
Le Kremlin-Bicêtre, 94275, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can immune cells predict herpesvirus danger in transplant patients?
- Muscle quality on MRI may foretell liver transplant success
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Better crystal ball for liver crisis: new scores put to the test